Krystal Biotech Analysts Boost Their Forecasts Following Upbeat Q1 Results-To The Moon - Tiger Brokers Online Investing Community - To The Moon

Like
Comment
Favorite

Krystal Biotech Analysts Boost Their Forecasts Following Upbeat Q1 Results

Benzinga05-06

Krystal Biotech Inc (NASDAQ:KRYS) reported upbeat earnings for the first quarter on Monday.

The company posted quarterly earnings of $1.83 per share which beat the analyst consensus estimate of $1.39 per share. The company reported quarterly sales of $116.357 million which beat the analyst consensus estimate of $112.132 million.

“Following a successful 2025, we are entering 2026 with strong momentum, including two potential registrational study readouts and continued global expansion for VYJUVEK,” said Krish S. Krishnan, Chairman and Chief Executive Officer of Krystal Biotech. “With three pipeline products receiving platform designation, each development milestone strengthens the regulatory dataset, which could accelerate future programs and potentially reduce development risk. This compounding advantage underscores the value of the platform model we have been building since day one.”

Krystal Biotech shares fell 1% to trade at $284.01 on Tuesday.

These analysts made changes to their price targets on Krystal Biotech following earnings announcement.

Evercore ISI Group analyst Gavin Clark-Gartner maintained Krystal Biotech with an Outperform rating and raised the price target from $295 to $300.
Citigroup analyst Yigal Nochomovitz maintained the stock with a Buy and raised the price target from $371 to $378.

Considering buying KRYS stock? Here’s what analysts think:

Photo via Shutterstock

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Like

Report

Comment

empty

No comments yet

Most Discussed

7x24

{"i18n":{"language":"en_US"},"data":{"share":"https://ttm.financial/m/news/2633940097?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-05-06 02:19","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2633940097","market":"hk","top_or_hot":-1,"title":"Krystal Biotech Analysts Boost Their Forecasts Following Upbeat Q1 Results","media":"Benzinga","content":"<html><body><p><strong><a href=\"https://laohu8.com/S/KRYS\">Krystal Biotech</a> Inc</strong> (NASDAQ:KRYS) reported upbeat earnings for the first quarter on Monday.</p>\n<p>The company posted quarterly earnings of $1.83 per share which beat the analyst consensus estimate of $1.39 per share. The company reported quarterly sales of $116.357 million which beat the analyst consensus estimate of $112.132 million.</p>\n<p>“Following a successful 2025, we are entering 2026 with strong momentum, including two potential registrational study readouts and continued global expansion for VYJUVEK,” said Krish S. Krishnan, Chairman and Chief Executive Officer of Krystal Biotech. “With three pipeline products receiving platform designation, each development milestone strengthens the regulatory dataset, which could accelerate future programs and potentially reduce development risk. This compounding advantage underscores the value of the platform model we have been building since day one.”</p>\n<p>Krystal Biotech shares fell 1% to trade at $284.01 on Tuesday.</p>\n<p>These analysts made changes to their price targets on Krystal Biotech following earnings announcement.</p>\n<ul>\n<li><a href=\"https://laohu8.com/S/EVR\">Evercore</a> ISI Group analyst Gavin Clark-Gartner maintained Krystal Biotech with an Outperform rating and raised the price target from $295 to $300.</li>\n<li>Citigroup analyst Yigal Nochomovitz maintained the stock with a Buy and raised the price target from $371 to $378.</li>\n</ul>\n<p><strong>Considering buying KRYS stock? Here’s what analysts think:</strong> </p>\n<figure><img decoding=\"async\" height=\"202\" loading=\"lazy\" sizes=\"(max-width: 1024px) 100vw, 1024px\" src=\"https://editorial-assets.benzinga.com/wp-content/uploads/2026/05/05141837/image-96-1024x202.png\" srcset=\"https://editorial-assets.benzinga.com/wp-content/uploads/2026/05/05141837/image-96-1024x202.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2026/05/05141837/image-96-300x59.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2026/05/05141837/image-96-768x152.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2026/05/05141837/image-96.png 1265w\" width=\"1024\"/></figure>\n<p><em>Photo via Shutterstock</em></p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Krystal Biotech Analysts Boost Their Forecasts Following Upbeat Q1 Results</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nKrystal Biotech Analysts Boost Their Forecasts Following Upbeat Q1 Results\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Benzinga </p>\n<p class=\"h-time\">2026-05-06 02:19</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p><strong><a href=\"https://laohu8.com/S/KRYS\">Krystal Biotech</a> Inc</strong> (NASDAQ:KRYS) reported upbeat earnings for the first quarter on Monday.</p>\n<p>The company posted quarterly earnings of $1.83 per share which beat the analyst consensus estimate of $1.39 per share. The company reported quarterly sales of $116.357 million which beat the analyst consensus estimate of $112.132 million.</p>\n<p>“Following a successful 2025, we are entering 2026 with strong momentum, including two potential registrational study readouts and continued global expansion for VYJUVEK,” said Krish S. Krishnan, Chairman and Chief Executive Officer of Krystal Biotech. “With three pipeline products receiving platform designation, each development milestone strengthens the regulatory dataset, which could accelerate future programs and potentially reduce development risk. This compounding advantage underscores the value of the platform model we have been building since day one.”</p>\n<p>Krystal Biotech shares fell 1% to trade at $284.01 on Tuesday.</p>\n<p>These analysts made changes to their price targets on Krystal Biotech following earnings announcement.</p>\n<ul>\n<li><a href=\"https://laohu8.com/S/EVR\">Evercore</a> ISI Group analyst Gavin Clark-Gartner maintained Krystal Biotech with an Outperform rating and raised the price target from $295 to $300.</li>\n<li>Citigroup analyst Yigal Nochomovitz maintained the stock with a Buy and raised the price target from $371 to $378.</li>\n</ul>\n<p><strong>Considering buying KRYS stock? Here’s what analysts think:</strong> </p>\n<figure><img decoding=\"async\" height=\"202\" loading=\"lazy\" sizes=\"(max-width: 1024px) 100vw, 1024px\" src=\"https://editorial-assets.benzinga.com/wp-content/uploads/2026/05/05141837/image-96-1024x202.png\" srcset=\"https://editorial-assets.benzinga.com/wp-content/uploads/2026/05/05141837/image-96-1024x202.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2026/05/05141837/image-96-300x59.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2026/05/05141837/image-96-768x152.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2026/05/05141837/image-96.png 1265w\" width=\"1024\"/></figure>\n<p><em>Photo via Shutterstock</em></p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4581","symbol_name":"高盛持仓","start_time":0,"source_url":"https://www.benzinga.com/news/26/05/52297479/krystal-biotech-analysts-boost-their-forecasts-following-upbeat-q1-results","article_id":"2633940097","we_media_id":"1052270027","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2633940097","pubTimestamp":1778005196,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Benzinga","introduction":"Stock Market Quotes, Business News, Financial News, Trading Ideas, and Stock Research by Professionals","home_visible":0,"id":"1052270027","head_image":"https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa"},"summary":"Krystal Biotech (KRYS) reported strong Q1 earnings, beating analyst estimates and with potential for future growth. Shares fell 1% on Tuesday.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4581":"高盛持仓","XBI":"SPDR S&P Biotech ETF","KRYS":"Krystal Biotech Inc.","BK4588":"碎股","BK4585":"ETF&股票定投概念","BK4139":"生物科技"},"translate_title":"Krystal Biotech分析师在第一季度业绩乐观后上调了预测","themeId":"11c8fbbf839f433c9d274cef5f173382","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"KRYS":1,"XBI":1.5},"content_text":"Krystal Biotech Inc (NASDAQ:KRYS) reported upbeat earnings for the first quarter on Monday.\nThe company posted quarterly earnings of $1.83 per share which beat the analyst consensus estimate of $1.39 per share. The company reported quarterly sales of $116.357 million which beat the analyst consensus estimate of $112.132 million.\n“Following a successful 2025, we are entering 2026 with strong momentum, including two potential registrational study readouts and continued global expansion for VYJUVEK,” said Krish S. Krishnan, Chairman and Chief Executive Officer of Krystal Biotech. “With three pipeline products receiving platform designation, each development milestone strengthens the regulatory dataset, which could accelerate future programs and potentially reduce development risk. This compounding advantage underscores the value of the platform model we have been building since day one.”\nKrystal Biotech shares fell 1% to trade at $284.01 on Tuesday.\nThese analysts made changes to their price targets on Krystal Biotech following earnings announcement.\n\nEvercore ISI Group analyst Gavin Clark-Gartner maintained Krystal Biotech with an Outperform rating and raised the price target from $295 to $300.\nCitigroup analyst Yigal Nochomovitz maintained the stock with a Buy and raised the price target from $371 to $378.\n\nConsidering buying KRYS stock? Here’s what analysts think: \n\nPhoto via Shutterstock","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport,express","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"hasMoreComments":false,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"isCrawlerRequest":true}